Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042)
In an effort to allow patients continued access to vorinostat outside of the base study, patients that are actively receiving study medication will discontinue from this study and receive vorinostat via another method supported by the SPONSOR (e.g. Named Patient Program (NPP)). For those institutions that do not allow receipt of an investigational therapy outside of a clinical trial, patients that are actively receiving study medication and
continue to meet eligibility will transition to an extension phase of the study and the base study will be closed.
The extension phase will begin as soon as the protocol amendment is implemented.
|Study Type:||Expanded Access What is Expanded Access?|
|Official Title:||Compassionate Use of Vorinostat (MK0683) for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00419367
|Study Director:||Medical Monitor||Merck Sharp & Dohme Corp.|